hEPO mRNA Synthesis Service
Human erythropoietin (hEPO) is a vital glycoprotein hormone that regulates erythropoiesis—the production of red blood cells. While recombinant hEPO proteins have long been the clinical standard for treating anemia associated with chronic kidney disease (CKD) and chemotherapy, hEPO messenger RNA (mRNA) technology represents a paradigm shift. By delivering the genetic blueprint for hEPO directly to the patient's cells, mRNA-based therapies enable the body to serve as its own "bioreactor," producing hEPO with natural post-translational modifications and a potentially superior pharmacokinetic profile. At CD BioGlyco, we leverage our extensive expertise in glycobiology and nucleic acid chemistry to provide high-purity hEPO mRNA synthesis services. Our platform is designed to overcome traditional manufacturing hurdles, offering researchers and drug developers a reliable source of optimized, translatable mRNA for protein replacement therapy and gene delivery studies.
Key Technologies
- High-Fidelity In Vitro Transcription (IVT)
We employ optimized T7 RNA polymerase systems to synthesize hEPO mRNA from linearized DNA templates. This process ensures high sequence accuracy and the ability to scale from microgram quantities for pilot studies to multi-gram levels for late-stage research.
- Advanced Capping & Tailing
Utilizing co-transcriptional capping technologies to produce a Cap-1 structure, we enhance mRNA stability and minimize innate immune recognition. This is coupled with precise enzymatic or template-encoded polyadenylation to ensure optimal half-life in vivo.
- Nucleotide Modification (N-Methylpseudouridine)
To bypass cellular defense mechanisms such as Toll-like receptors (TLRs), we incorporate modified nucleotides like N-methylpseudouridine. This modification significantly reduces immunogenicity while boosting the translational capacity of the hEPO mRNA.
hEPO mRNA Synthesis: Precision Engineering for Next-Generation Anemia Therapeutics
At CD BioGlyco, our hEPO mRNA synthesis service is a cornerstone of our therapeutic nucleic acid development platform. We provide a full-spectrum therapeutic oligonucleotide synthesis service that translates complex genetic designs into high-performing therapeutic candidates. Our expanded scope includes:
- Custom hEPO Construct Design: Our team provides end-to-end template construction, including gene synthesis, cloning into specialized expression vectors, and precise linearization. We ensure the DNA template contains the optimal promoter sequences and encoded poly(A) stretches to guarantee high-fidelity transcription.
- Modified mRNA Synthesis: We offer an extensive library of modified nucleosides to enhance mRNA stability and reduce immunogenicity. Our capabilities include the full replacement or partial incorporation of N1-methylpseudouridine, 5-methoxyuridine (5moU), and 5-methylcytidine (m5C).
- Capping and Polyadenylation: This includes traditional enzymatic capping and state-of-the-art co-transcriptional capping to produce a pure Cap-1 structure. For the 3' end, we offer both template-encoded poly(A) tails for length homogeneity and enzymatic tailing for extended stability.
- Scale-Up & Purity Options: Our facility is equipped to handle projects from pilot-scale research to large-scale pre-clinical batches. We utilize high-resolution purification techniques to ensure the removal of all process-related impurities, such as double-stranded RNA (dsRNA) and residual DNA templates.
Workflow
Sequence Design & Codon Optimization
We begin by analyzing the target hEPO sequence. Using proprietary algorithms, we perform codon optimization to enhance translation speed and mRNA stability while avoiding secondary structures that could interfere with the IVT process.
Template Preparation & Linearization
The optimized sequence is cloned into a high-copy plasmid vector. We then perform precise linearization using restriction enzymes, followed by rigorous purification to ensure a "clean" template free of RNases and plasmid debris.
IVT Reaction
The linearized DNA serves as a template for enzymatic synthesis. We optimize the reaction conditions—including NTP concentrations and buffer components—to maximize yield and ensure the production of full-length hEPO transcripts.
Co-transcriptional Capping and Tailing
During or immediately following transcription, we apply capping (Cap-1) and poly(A) tailing. This step is critical for protecting the hEPO mRNA from exonuclease degradation and ensuring efficient recruitment of the ribosome.
Multi-Step Purification
To remove impurities such as dsRNA, truncated transcripts, and residual enzymes, we utilize high-performance liquid chromatography (HPLC) or tangential flow filtration (TFF). This results in exceptionally pure mRNA with minimal inflammatory potential.
Comprehensive Quality Control (QC)
Every lot undergoes stringent testing, including fragment analysis for integrity, concentration measurement, endotoxin assays, and functional testing to confirm hEPO protein expression.
Applications
Anemia Therapeutics Development
Our hEPO mRNA serves as a primary tool for developing treatments for chronic kidney disease and chemotherapy-induced anemia. It enables endogenous production of EPO, providing a more stable and natural therapeutic alternative to recombinant protein injections.
Protein Replacement Therapy
As a benchmark model for secreted proteins, hEPO mRNA is used to validate platform technologies for enzyme deficiencies. It allows researchers to study translation efficiency, secretion pathways, and protein folding under physiological conditions.
Non-Viral Delivery System (DDS) Validation
hEPO mRNA is frequently used as a functional reporter to evaluate lipid nanoparticles (LNPs). Researchers precisely measure delivery potency by monitoring serum hEPO levels and reticulocyte counts in animal models following administration.
Regenerative Medicine & Neuroprotection
hEPO mRNA is utilized in research concerning tissue repair and neuroprotection. It facilitates the exploration of treatments for ischemic injury and wound healing by providing transient, localized EPO expression for cellular protection.
Advantages
Minimal Innate Immunogenicity
By incorporating high-grade N1-methylpseudouridine and utilizing advanced purification methods to remove dsRNA, we ensure our mRNA minimizes the induction of interferon-mediated immune responses.
High Capping Efficiency
Our co-transcriptional capping process consistently achieves >95% Cap-1 incorporation, which is vital for the stability and long-term activity of hEPO mRNA in biological systems.
Customizable Modification Profiles
We offer a wide range of chemical modifications and tailing options, allowing clients to fine-tune the half-life and tissue-specific expression of their hEPO candidates.
Rigorous Quality Assurance
Every batch is accompanied by a detailed certificate of analysis (CoA) including purity, integrity, and safety metrics, ensuring reproducible results for your critical therapeutic research.
Frequently Asked Questions
Customer Review
"The hEPO mRNA synthesized by CD BioGlyco showed remarkable stability in our in vivo models. We observed a sustained increase in hemoglobin levels that outperformed our previous benchmarks."
— A.H., Biopharmaceutical Company
"We struggled with low yields and high immunogenicity from other suppliers. Switching to CD BioGlyco's HPLC-purified hEPO mRNA made a significant difference in our LNP delivery studies."
— G.H., Innovative Biotech Startup
"The team at CD BioGlyco helped us design a custom UTR sequence that tripled our hEPO expression levels in renal cell lines. Their expertise in the therapeutic nucleic acid development platform is evident in the quality of the final product."
— S.H., Principal Investigator
Associated Services
CD BioGlyco is your dedicated partner for high-performance hEPO mRNA synthesis. By integrating cutting-edge IVT technologies with rigorous purification and glycobiology expertise, we deliver mRNA products that meet the stringent demands of modern therapeutic development. Please feel free to contact us for detailed information, pricing, or to discuss the specific needs of your project.